このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Innovative Approaches for Minor Consent: Consent 2.0

2021年3月25日 更新者：Amelia Knopf、Indiana University

Innovative Approaches for Minor Consent: Consent 2.0 - A Multi-Center Study of the Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN)

The purpose of this study is to examine how the consent process affects the acceptability of participation in biomedical HIV prevention trials, from the perspective of behaviorally high-risk minors and the parents of minor adolescents.

調査の概要

状態

完了

条件

介入・治療

詳細な説明

Potential participants will be recruited from clinical settings and HIV testing centers. If interested in participation, they will take a short Computer Assisted Self-Interview (CASI) screening survey to determine eligibility. Those eligible will take part in the one-day study visit at that time or will provide contact information to set up the study visit at a later date.

All study participants will attend a one-day study visit at their respective study site. Upon arrival, participants will complete a CASI that collects demographic, social, behavioral, and attitudinal measures. Next, participants will take part in a simulated consent process for two hypothetical trials modeled after ATN 113 and HPTN 077. Study procedures differ for adolescents and parents, so each group is described separately below:

Adolescent Participants: For each hypothetical trial, research staff will lead the participant through a simulated consent process consistent with their randomized consent condition. Then, the participant will complete a CASI assessing Willingness to Participate (WTP) and will work with research staff to complete the University of San Diego (UCSD) Brief Assessment of Capacity to Consent (UBACC).

Parent Participants: For each hypothetical trial, research staff will review the informed consent forms with the parent. The parent will complete a CASI with three vignettes that describe each of the three possible consent conditions. Parents will rate the acceptability of each vignette. Then, the participant will work with research staff to complete the UCSD Brief Assessment of Capacity to Consent (UBACC). Finally, the participant will answer a series of questions via CASI.

A subset of 6-8 adolescents and 6-8 parents per study site will complete a debriefing interview assessing adolescent and parent perspectives on the various consent conditions in greater depth, and to better understand the role of study features, family, and adolescent characteristics in willingness to participate/willingness to support the hypothetical research studies.

研究の種類

介入

入学 (実際)

254

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

  • アメリカ
    • Colorado
      • Aurora、Colorado、アメリカ、80045
        • Children's Hospital Colorado/Univ of Colorado SOM
    • Florida
      • Tampa、Florida、アメリカ、33606
        • University of South Florida
    • Illinois
      • Chicago、Illinois、アメリカ、60637
        • University of Chicago
    • Maryland
      • Baltimore、Maryland、アメリカ、21287
        • Johns Hopkins University/SOM

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

14年～17年 (子)

健康ボランティアの受け入れ

はい

受講資格のある性別

全て

説明

Note: Age limits apply to adolescent participants and to the adolescent children of parent participants.

Adolescent Inclusion Criteria

  • Age 14-17 inclusive
  • Able to read and speak English
  • HIV status is negative or unknown
  • Engaged in high-risk sexual activity in the last six months

Adolescent Exclusion Criteria

  • Child of a parent already enrolled in the study

Parent Inclusion Criteria

  • Able to read and speak English
  • Parent or guardian of an adolescent who is between ages 14-17
  • The parent/guardian's adolescent's HIV status is either negative or unknown

Parent Exclusion Criteria

  • Parent of a child already enrolled in the study

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか？

デザインの詳細

  • 主な目的：他の
  • 割り当て：ランダム化
  • 介入モデル：並列代入
  • マスキング：なし（オープンラベル）

武器と介入

参加者グループ / アーム
介入・治療
アクティブコンパレータ：Adolescents: Consent Condition 1
Autonomous minor consent
他の：Autonomous minor consent
Consent requirement where the participant is not required to get anyone's permission to participate in the trial.
アクティブコンパレータ：Adolescents: Consent Condition 2
Adult permission required
他の：Adult permission required
Consent requirement where the participant is required to obtain an adult's permission to participate in the trial.
アクティブコンパレータ：Adolescents: Consent Condition 3
Parental permission required
他の：Parental permission required
Consent requirement where the participant is required to obtain their parent's permission to participate in the trial.
アクティブコンパレータ：Parents: Consent Conditions 1-3
Autonomous minor consent, adult permission required, and parental permission required
他の：Autonomous minor consent
Consent requirement where the participant is not required to get anyone's permission to participate in the trial.
他の：Adult permission required
Consent requirement where the participant is required to obtain an adult's permission to participate in the trial.
他の：Parental permission required
Consent requirement where the participant is required to obtain their parent's permission to participate in the trial.

この研究は何を測定していますか？

主要な結果の測定

結果測定
メジャーの説明
時間枠
Mean Adolescent WTP Scores
時間枠：Day 1

Comparing mean adolescent Willingness to Participate (WTP) scores across the three consent conditions and two trial types.

WTP scores are based on the response to the question: "If offered the chance, how likely would you be to participate in the study?" Responses are collected using a Likert scale (definitely not participate, probably not participate, might or might not participate, probably participate, definitely participate) and converted to a numeric score with values ranging from 1 (definitely not participate) to 5 (definitely participate) for analysis.
Day 1
Mean Parent WTS Scores
時間枠：Day 1

Comparing mean parent Willingness to Support (WTS) scores across the three consent conditions and two trial types.

WTS scores are based on the response to the question: "This is an acceptable approach to consent for your teenager's participation in the study." Responses are collected using a Likert scale (strongly disagree, disagree, neither disagree nor agree, agree, strongly agree) and converted to a numeric score with values ranging from 1 (strongly disagree) to 5 (strongly agree) for analysis.
Day 1
Effects of the Study Agent (Stage of Development and Method of Delivery) on High-risk Minor Adolescents' WTP Scores
時間枠：Day 1
This data reflects adolescent Willingness to Participate (WTP) scores by study agent/trial type. After review of hypothetical consent documents for 2 study agents in different stages of development and with different methods of delivery (based on real-world studies ATN 113 and HPTN 077), adolescents are asked "If offered the chance, how likely would you be to participate in the study?" Responses are collected using a Likert scale (definitely not participate, probably not participate, might or might not participate, probably participate, definitely participate) and converted to a numeric score with values ranging from 1 (definitely not participate) to 5 (definitely participate) for analysis.
Day 1
Effects of the Study Agent (Stage of Development and Method of Delivery) on Parents' Acceptability Scores
時間枠：Day 1
After review of hypothetical consent documents for 2 study agents in different stages of development and with different methods of delivery (based on real-world trials ATN 113 and HPTN 077), parents are presented with vignettes for the 3 different consent conditions (autonomous minor consent, adult permission required, parental permission required) and asked "How acceptable is this approach to research consent?". Responses are collected on a Likert scale (completely unacceptable, unacceptable, neither unacceptable not acceptable, acceptable, completely acceptable) and converted to a numeric score with values ranging from 1 (definitely not acceptable) to 5 (definitely acceptable) for analysis.
Day 1

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

Indiana University

協力者

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

捜査官

  • 主任研究者：Amy Knopf, PhD, MPH, RN、Indiana University School of Medicine
  • スタディディレクター：Matthew Psioda, PhD、University of North Carolina, Chapel Hill

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2017年11月7日

一次修了 (実際)

2019年9月15日

研究の完了 (実際)

2019年9月15日

試験登録日

最初に提出

2017年8月3日

QC基準を満たした最初の提出物

2017年8月3日

最初の投稿 (実際)

2017年8月8日

学習記録の更新

投稿された最後の更新 (実際)

2021年4月22日

QC基準を満たした最後の更新が送信されました

2021年3月25日

最終確認日

2021年3月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 17-0538
  • 5U24HD089880-02 (米国 NIH グラント/契約)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

De-identified study data will be made available in the NICHD Data and Specimen Hub (DASH), a centralized resource for researchers to store de-identified data from NICHD supported studies for use in secondary research. NICHD DASH is a free public resource designed for the scientific research community.

IPD 共有時間枠

Data will be made available after data analyses have been completed, data has been de-identified, and all DASH submission requirements have been met and approved. Data will be available according to NICHD DASH timelines.

IPD 共有アクセス基準

Please see DASH guidelines for access criteria.

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • SAP

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

HIVの臨床試験

Autonomous minor consentの臨床試験

類似の治験を検索

スポンサーと協力者

医学的状態

薬物療法

CROs by country

CROs in Togo

条件

まれな病気

薬物療法

ダイエットサプリメント

スポンサー/協力者

場所

3
購読する